ACTIVE FUNDING

Intracellular switching using genetically engineered protein microdomains; NIH/NIGMS 1R01GM114839-02; J. Andrew MacKay, PI; April 1, 2015 – March 31, 2020.

Protein-polymer nanomedicine for Sjögren’s Syndrome; NIH/NEI 1R01EY026635-01; J. Andrew MacKay; Sarah Hamm-Alvarez, multi-PI; Sept 1, 2016 – March 31, 2021.

Protein-polymer nanomedicines for ocular therapy; Whittier Foundation; Ed Crandall PI (J. Andrew MacKay, Co-investigator); March 1, 2016-December 31, 2017.

An experimental approach to maculopathy; NIH/NEI R01EY001545-34; David Hinton, PI (J. Andrew MacKay, Co-investigator); April 1, 2012 - March 31, 2017.

Microtubule-based transport in lacrimal gland function; NIH/NEI 1R01EY011386-16; Hamm-Alvarez, PI (J. Andrew MacKay, Co-investigator); July 1, 2016 - June 30, 2021.

 

PREVIOUSLY HELD FUNDING

Targeting liposomal drug and gene delivery and the osmotic pressure of tumors; Howard Hughes Medical Institute Pre-doctoral Fellowship; J. Andrew MacKay, PI; August 1, 2001 - March 31, 2005.

pH sensitive elastin-like-peptides for tumor targeting; NIH/NCI F32 CA123889 Kirschstein National Research Service Award; J. Andrew MacKay, PI; July 1, 2006 - June 30, 2008.

Hepatic trafficking and anti-tumor activity of genetically engineered glyco-celles; NIH/NIDDK P30 DK048522-15 Pilot; J. Andrew MacKay, PI; March 1, 2009 - February 28, 2010.

Positron emission tomography of peptide-drug nanoparticles targeted to the tumor blood supply; American Cancer Society IRG-58-007-48 Pilot; J. Andrew MacKay, PI; June 1, 2009 - May 30, 2010.

Ad5 fiber entry and trafficking in lacrimal acini; NIH/NEI R01 EY017293-04S1; Sarah Hamm-Alvarez, PI (J. Andrew MacKay, Co-PI); August 1, 2009 - March 31, 2011.

Nanoparticle encapsulated alphaB crystallin chaperone peptide as a therapeutic agent in atrophic age-related macular degeneration; USC LACTSI Pilot; David Hinton, PI (J. Andrew MacKay, Co-investigator); November 1, 2010 - March 31, 2011.

Biomolecular engineering of sustained-release disintegrins for cancer therapy; Wright Foundation Young Investigator; J. Andrew MacKay, PI; July 1, 2011 - June 31, 2012.

Diagnostic imaging of smart genetically engineered nanomedicines; USC Ming Hsieh Institute Pilot; J. Andrew MacKay, PI; November 1, 2011 - October 31, 2012.

A rapid, reversible switch for controlling intracellular trafficking; NIH/NIBIB R21 EB012281; J. Andrew MacKay, PI; July 1, 2010 - June 30 2013.

Preclinical evaluation of sustained-release disintegrins for cancer therapy; SC-Clinical and Translational Science Institute Multidisciplinary Pilot Project; J. Andrew MacKay. PI; July 1, 2012 - June 30, 2013.   
Genetically Engineered Cancer Nanomedicines; USC Whittier Foundation Pilot; J. Andrew MacKay, PI; January 1, 2012-December 31, 2013.

Diagnostic imaging of smart genetically engineered nanomedicines; USC Ming Hsieh Institute; J. Andrew MacKay, PI; September 1, 2013 - August 31, 2014.

VRPD: Treatment of the Cornea using Transcytotic Delivery into the Tear Film; W81XWH-12-1-0538, USAMRAA Vision Research Hypothesis Award; J. Andrew MacKay, PI; September 30, 2012 - September 29, 2015.

Bispecific hybrid nanoworms for immunotherapy of B-cell lymphoma; USC Ming Hsieh Institute; J. Andrew MacKay, PI; September 1, 2014 - August 31, 2015.

A Thermo-responsive Biopharmaceutical to Enhance the Tear Production of Lacritin; NIH/NEI R41 EY 022514-01A1;    Sandeep Samudre, PI (J. Andrew MacKay, Co-investigator); September 30, 2013 - September 29, 2015. (NCE)

Genetically engineered nanoparticles for cancer imaging and drug delivery; Stop Cancer Research Career Development Award; J. Andrew MacKay, PI; March 1, 2011 - February 28, 2016.

Encapsulation of Rhesus theta defensin-1 (RTD-1) in PEG-PLGA nanoparticles for aerosol delivery in CF; Webb Foundation; Paul Beringer, PI (J. Andrew MacKay, Co-investigator); November 1, 2014 - October 31, 2015.

Proof-of-concept fusion of a protein-polymer to hemoglobin; SAIMA Biopharmaceuticals; J. Andrew MacKay, PI; June 15, 2015- November 15, 2015.

Bispecific hybrid nanoworms for immunotherapy of B-cell lymphoma; USC Ming Hsieh Institute; J. Andrew MacKay, PI; June 1, 2016 - August 31, 2015.